Scribe Therapeutics shared its financial results for the last quarter and updates on its ongoing drug trials.

Nov 12, 2026, 4:32 PM ETResultsRead the original at SEC EDGAR

Good for SCTX

Scribe reported $174.2 million in cash, equivalents, and marketable securities, with funding into the first half of 2029. Its Sanofi collaboration also expanded, and human trial results are still pending, but the update supports its outlook.

SCTX · Scribe Therapeutics, Inc.

AI read · Good for SCTX

The AI's read

That cash gives Scribe time to keep developing its treatments, and its expanded Sanofi work now includes its gene-silencing technology. Its first human study is underway, but results are not expected until 2027. The funding and added collaboration support a favorable read, though the treatments have not yet shown results in people.

Get alerts for SCTX

Follow Scribe Therapeutics, Inc. (SCTX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for SCTX

Free on the App Store and Google Play, or on the web.